• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals, Inc. - Common Stock (NQ:ELDN)

2.780 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eledon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
September 09, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
September 03, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
June 25, 2026
From Natera, Inc.
Via Business Wire
Eledon Pharmaceuticals Inc (NASDAQ:ELDN) Reports Narrower Q4 Loss and Positive Clinical Data for Tegoprubart ↗
March 19, 2026
Via Chartmill
News headline image
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
June 22, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
June 08, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
June 04, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
May 20, 2026
Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
March 19, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
March 16, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
March 10, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
March 04, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
January 23, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
January 08, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
December 01, 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Tuesday's after hours session: top gainers and losers ↗
November 18, 2025
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
November 18, 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
November 14, 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
November 14, 2025
 
Via Benzinga
News headline image
Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering
November 12, 2025
Irvine, CA – November 12, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a significant decline in its stock value today, plummeting by 17.8% in premarket trading. This sharp drop comes on the... 
Via MarketMinute
Topics Initial Public Offering Intellectual Property Regulatory Compliance
News headline image
Top movers in Wednesday's pre-market session ↗
November 12, 2025
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
November 12, 2025
 
Via Benzinga
News headline image
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
November 11, 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
November 10, 2025
San Diego, CA – November 10, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a dramatic collapse in its stock price, shedding nearly 50% of its value following the announcement of mixed results... 
Via MarketMinute
News headline image
What's going on in today's after hours session ↗
November 07, 2025
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
What's going on in today's session ↗
November 07, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap